These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10229097)

  • 1. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
    Ressing ME; de Jong JH; Brandt RM; Drijfhout JW; Benckhuijsen WE; Schreuder GM; Offringa R; Kast WM; Melief CJ
    Eur J Immunol; 1999 Apr; 29(4):1292-303. PubMed ID: 10229097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
    Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
    J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
    Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
    J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
    J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
    mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
    van der Burg SH; Ressing ME; Kwappenberg KM; de Jong A; Straathof K; de Jong J; Geluk A; van Meijgaarden KE; Franken KL; Ottenhoff TH; Fleuren GJ; Kenter G; Melief CJ; Offringa R
    Int J Cancer; 2001 Mar; 91(5):612-8. PubMed ID: 11267969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
    Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
    Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
    Oerke S; Höhn H; Zehbe I; Pilch H; Schicketanz KH; Hitzler WE; Neukirch C; Freitag K; Maeurer MJ
    Int J Cancer; 2005 May; 114(5):766-78. PubMed ID: 15609316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
    Ressing ME; van Driel WJ; Celis E; Sette A; Brandt MP; Hartman M; Anholts JD; Schreuder GM; ter Harmsel WB; Fleuren GJ; Trimbos BJ; Kast WM; Melief CJ
    Cancer Res; 1996 Feb; 56(3):582-8. PubMed ID: 8564975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
    Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
    Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.
    Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E
    Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
    Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.